• Latest
    • Big pharma
    • Biotechnology
    • CRISPR
    • Generics
    • Unified Patent Court
  • Regions
    • Americas
    • Europe
    • Asia
    • Asia-Pacific
  • Careers
  • Events
    • Conferences
    • Conference Videos
    • Webinars
  • Directory
  • Magazines
  • About
  • Contact
  • Newsletter
  • Login
  • Subscribe
  • Home
  • About
  • Contact
  • Newsletter
  • Login


Request Trial
  • Home
  • Copyright compliance in the life sciences industry
race-uphill-sand-dune
31 March 2014Kate Alzapiedi

Copyright compliance in the life sciences industry

Now that the rapid exchange of scientific research and product information across international borders has become commonplace, rights holders and users of published material face an increasingly complex set of issues involving reuse rights, permissions, restrictions and fees.

Already registered?

Login to your account


If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.

For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Amgen and subsidiary dealt $20m blow over rodent antibody tech
15 June 2026   Unanimous jury finds willful infringement, with the possibility of a trebled award and a much larger feud still to come.
Careers
Ex-Simmons head of IP joins Carpmaels & Ransford
15 June 2026   Highly experienced partner is the second big name to join the firm this year, expanding its Engineering & Tech practice and beefing up its IP disputes work.
Americas
Moderna: BioNTech is claiming work ‘it never did’
12 June 2026   In a strong response to BioNTech, Moderna argues its next-gen vaccine is built on a fundamentally different design from the German biotech’s—setting up a scrap over whether a key patent should have been granted.


Editor's picks

Hikma v Amarin: Six takeaways from the pivotal ruling
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026

Editor's picks

Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026

More features

Kirkland & Ellis adds leading barrister in London
Kilpatrick adds tech patent litigator and China expert to Chicago office
Litigator from Brown Rudnick moves firms to chair practice
Patent office fee increases: What applicants must know
IndiaMart v CDSCO: A test of intermediary liability
Six Summit takeaways: In-person IP, agentic AI and ‘infollution’ risks
Arnold & Porter adds tech litigator in San Francisco
To cite or not to cite: How can we avoid misuse of AI in court?

  • Home
  • News
  • About us
  • Contact
  • Terms of Use
  • Privacy Policy
  • Terms of Subscription

LSIPR
Newton Media Ltd
Kingfisher House
21-23 Elmfield Road
BR1 1LT
United Kingdom

  • Twitter
  • Linkedin